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Co-Encapsulation of Anti-BMP2 Monoclonal Antibody and Mesenchymal Stem
Cells in Alginate Microspheres for Bone Tissue Engineering
Abstract
Recently, it has been shown that tethered anti-BMP2 monoclonal antibodies (mAbs) can trap BMP ligands
and thus provide BMP inductive signals for osteo-differentiation of progenitor cells. The objectives of this
study were to: (1) develop a co-delivery system based on murine anti-BMP2 mAb-loaded alginate
microspheres encapsulating human bone marrow mesenchymal stem cells (hBMMSCs); and (2)
investigate osteogenic differentiation of encapsulated stem cells in alginate microspheres in vitro and in

vivo. Alginate microspheres of 1 ± 0.1 mm diameter were fabricated with 2 × 106 hBMMSCs per mL of
alginate. Critical-size calvarial defects (5 mm diameter) were created in immune-compromised mice and
alginate microspheres preloaded with anti-BMP mAb encapsulating hBMMSCs were transplanted into
defect sites. Alginate microspheres pre-loaded with isotype-matched non-specific antibody was used as
the negative control. After 8 weeks, micro CT and histologic analysis were used to analyze bone
formation. In vitro analysis demonstrated that anti-BMP2 mAbs tethered BMP2 ligands that can activate
the BMP receptors on hBMMSCs. The co-delivery system described herein, significantly enhanced
hBMMSC-mediated osteogenesis, as confirmed by the presence of BMP signal pathway-activated
osteoblast determinants Runx2 and ALP. Our results highlight the importance of engineering the
microenvironment for stem cells, and particularly the value of presenting inductive signals for osteodifferentiation of hBMMSCs by tethering BMP ligands using mAbs. This strategy of engineering the
microenvironment with captured BMP signals is a promising modality for repair and regeneration of
craniofacial, axial and appendicular bone defects.
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Abstract
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Recently, it has been shown that tethered anti-BMP2 monoclonal antibodies (mAbs) can trap BMP
ligands and thus provide BMP inductive signals for osteo-differentiation of progenitor cells. The
objectives of this study were to: (1) develop a co-delivery system based on murine anti-BMP2
mAb-loaded alginate microspheres encapsulating human bone marrow mesenchymal stem cells
(hBMMSCs); and (2) investigate osteogenic differentiation of encapsulated stem cells in alginate
microspheres in vitro and in vivo. Alginate microspheres of 1 ± 0.1 mm diameter were fabricated
with 2 × 106 hBMMSCs per mL of alginate. Critical-size calvarial defects (5 mm diameter) were
created in immune-compromised mice and alginate microspheres preloaded with anti-BMP mAb
encapsulating hBMMSCs were transplanted into defect sites. Alginate microspheres pre-loaded
with isotype-matched non-specific antibody was used as the negative control. After 8 weeks,
micro CT and histologic analysis were used to analyze bone formation. In vitro analysis
demonstrated that anti-BMP2 mAbs tethered BMP2 ligands that can activate the BMP receptors
on hBMMSCs. The co-delivery system described herein, significantly enhanced hBMMSCmediated osteogenesis, as confirmed by the presence of BMP signal pathway-activated osteoblast
determinants Runx2 and ALP. Our results highlight the importance of engineering the
microenvironment for stem cells, and particularly the value of presenting inductive signals for
osteo-differentiation of hBMMSCs by tethering BMP ligands using mAbs. This strategy of
engineering the microenvironment with captured BMP signals is a promising modality for repair
and regeneration of craniofacial, axial and appendicular bone defects.
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1. Introduction
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Currently, reconstruction of missing or damaged bone can be accomplished by an array of
surgical procedures [1,2]. Autologous bone has been considered the “gold standard” for
bone augmentation. Autologous and allogenic bone grafts currently comprise more than
90% of grafts performed each year [3,4]. However, there are several disadvantages
associated with this methodology, such as donor site morbidity, hematoma, inflammation,
and the high cost of bone harvesting procedures [5,6]. The ultimate goal of bone tissue
engineering is the fabrication of a construct that matches the physical and biological
properties of the natural bone tissue, without the drawbacks imposed by autologous or
allogenic bone grafts. The extensive distribution of stem cells in many adult tissues, with
their ability to give rise to multiple specialized cell types, has made them an attractive target
for applications in tissue engineering. Mesenchymal stem cells (MSCs), such as human bone
marrow mesenchymal stem cells (hBMMSCs), can differentiate into one of many cell
lineages, including craniofacial bone osteoblasts, depending on the nature of the
environmental signals that they receive [7-9]. Both preclinical and clinical studies have
shown the application of hBMMSCs to be a promising treatment modality for generating
new bone through stem cell-mediated bone tissue engineering [10-12].
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To guide the differentiation of hBMMSC, it may be necessary and desirable to deliver an
appropriate signal that is specific to the desired lineage/phenotype, and hence, exogenous
growth factors have been delivered along with stem cells. It is well known that stem cellmediated bone regeneration is partially controlled by the recipient local microenvironment,
including the presence of growth factors, immune cells and cytokines [13-16]. However,
there are a number of limitations to the application of exogenous growth factors, including
significant side effects, reduced efficacy compared to endogenous counterparts, high cost,
difficulty of achieving optimal kinetics for delivery, and temporal and spatial requirements
for their availability [16-19]. As an alternative to using recombinant human bone
morphogenetic protein 2 (rhBMP2) as an exogenous growth factor, investigators have
recently shown the ability of specific monoclonal antibodies (mAb) directed against BMP2
to capture endogenous BMP2 ligands from the engraftment site and present them to
progenitor stem cells, promoting bone repair and regeneration [20, 21]. Therefore, one can
envision that combining the stem cells with antibodies selected for their capacity to capture
therapeutic ligands could enhance the quality and quantity of stem cell-mediated bone
regeneration.
In addition, it is also well known that the cell delivery vehicle helps to dictate the success of
regenerative therapy by improving the in vivo performance of stem cells. Several types of
scaffolds have been used to support growth and differentiation of progenitor cells for bone
regeneration, including natural polymers such as alginates. In previous studies, we have
utilized alginate hydrogels as a scaffold for the encapsulation of dental-derived adult MSCs
[23,24]. Alginates are natural hetero-polysaccharides with unique properties, including
gentle gelation behavior, biodegradability, biocompatibility, ease of cell encapsulation/cell
recovery, and chemical versatility, making them useful for the encapsulation of cells and
bioactive molecules that can be used to facilitate minimally invasive surgical procedures
[38-40]. Therefore, in seeking a platform for bone tissue engineering, we chose to utilize an
RGD-coupled alginate hydrogel as the scaffold for the simultaneous encapsulation of
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hBMMSCs with an anti-BMP2 mAb to capture endogenous BMP2 growth factor. We
hypothesized that this combination of vehicle, MSCs, and mAbs would provide an effective
method for improving the osteogenic differentiation of these stem cells.

2. Materials and Methods
2.1. Antibodies
We used clone 3G7, a mouse anti-BMP2 IgG2 monoclonal antibody (mAb) (Abnova,
Taipei, Taiwan). An isotype-matched mAb (Iso mAb) with no specificity for BMP2 was
utilized as the negative control.
2.2. Stem cell culture and flow cytometry analysis
Human bone marrow mesenchymal stem cells (hBMMSCs), processed from marrow
aspirates of normal human adult volunteers (20–35 years of age) according to a previously
published method [22], were purchased from Poietic Technologies (Gaithersburg, MD).
hBMMSCs were cultured in !-MEM (Invitrogen, Grand Island, NY) supplemented with
15% Fetal Bovine Serum (FBS, Invitrogen, San Diego CA), 100 units/mL penicillin
(Invitrogen), and 100 "g/mL streptomycin (Invitrogen). Passage four cells were used for all
experiments.
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To characterize the specificity of our murine anti-BMP2 mAb (3G7), hBMMSCs were
cultured and analyzed by flow cytometry. This procedure evaluated the presence or absence
of an immune complex formed between the anti-BMP2 mAb and the BMP2 ligand that
binds with the BMP2 receptor on hBMMSCs. Recombinant human bone morphogenetic
protein (rhBMP2, Medtronic, Minneapolis, MN) was used as a growth factor standard.
Briefly, rhBMP2 (100 ng/mL) was incubated with anti-BMP2 mAb (25 "g/mL) for 30 min
at 4°C and the resulting immune complex was incubated with hBMMSCs. The immune
complex was immunofluorescently detected using phycoerythrin-conjugated goat antimouse Ab (Becton Dickinson, Franklin Lakes, NJ). The intensity of fluorescent labeling was
determined by measuring the mean fluorescent intensity (MFI) with a flow cytometer
(FACS Calibur; Becton Dickinson). The experiment was repeated using an type-matched
non- specific mAb (Iso mAb) as the negative control.
2.3. In vitro osteogenic differentiation
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To study the effects of anti-BMP2 mAb on osteogenesis of hBMMSCs in vitro, 1 × 105
hBMMSCs were cultured in 6-well plates in culture media containing !-MEM (Invitrogen),
15% FBS (Invitrogen), 100 units/mL penicillin (Invitrogen), and 100 "g/mL streptomycin
(Invitrogen); and supplemented in one of the following ways: (1) recombinant human BMP2
(rhBMP2) at 100 ng/mL, serving as a positive control; (2) anti-BMP2 mAb (25"g/mL) + rhBMP2 (100 ng/mL); (3) non-specific isotype mAb (25 "g/mL) + rhBMP2 (100 ng/mL),
serving as an antibody control; and 4) no further supplementation, serving as a treatment
control. The culture dishes were first coated with either mAb or non-specific isotype mAb to
immobilize the mAbs, non-specific binding sites were blocked with bovine serum albumin
(0.5 mg/mL BSA, Invitrogen), and rh-BMP2 was added. After allowing 60 minutes for the
rh-BMP2 ligand to bind, the dishes were washed thoroughly with PBS to remove free rhBMP2 ligand. The medium was changed twice per week.
After two weeks in culture, the differentiation of the hBMMSCs was analyzed using
Alizarin red staining. Briefly, hBMMSC cultures were washed twice with PBS, fixed for 1
min in 60% isopropanol, and rehydrated with distilled water. They were then stained with
Alizarin red S dye solution for 5 min and excess dye was removed by washing twice with
deionized water. Retained Alizarin red S was quantified using NIH ImageJ software
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(Version 1.64, NIH, Bethesda, MD) by determining the area positive for dye staining
expressed as a fraction of the total area.
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After two weeks in culture, the differentiation of hBMMSCs was analyzed using Western
blot analysis. Briefly, the cells were washed twice with PBS and lysed with protein
extraction buffer (Bio-Rad, Irvine, CA) for 30 sec. The supernatant was cleared by
centrifugation and the protein concentration was determined using a BCA assay (Pierce,
Rockford, IL) by extrapolation to a known BSA standard concentration by serial dilution
across one order of magnitude. Equal amounts of protein extracts were fractionated to size
by electroporation in 10% sodium dodecyl sulfate-polyacrylamide gels (PAGE), and the
size-resolved proteins were electrophoretically transferred to a nitrocellulose membrane
(Bio-Rad). The nitrocellulose membrane was incubated with rabbit antibody directed against
phospho-Smad1 (Santa Cruz Biotechnology, Dallas, TX) or Runx2 (Abcam, Cambridge,
MA). Immune-protein complexes were detected using a secondary antibody at 1:500
(polyclonal goat anti-rabbit IgG/HRP, EMD Millipore, Billerica, MA). The membranes
were stripped and re-probed with an antibody directed against the housekeeping gene betaactin (Abcam) to ensure that equal mass was loaded to each lane. The chemiluminescent
reagent (Amersham Life Science, Pittsburgh, PA) was added to the membrane for 1 min and
exposed to x-ray film for variable periods (Thermo Scientific, Rockford, IL) to produce
images.
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A colorimetric p-nitrophenyl phosphate assay (Abcam) was utilized to measure the alkaline
phosphatase (ALP) activity of hBMMSCs in the culture conditions described above. The
cells were washed three times with PBS, collected by centrifugation, lysed, and then the
ALP reaction buffer was added to each sample. The level of ALP activity was normalized to
the amount of total DNA in each of the cell lysates. Normal control serum (Stanbio, Boerne,
TX) containing a known ALP concentration was used as a standard for extrapolation of
unknown values.
2.4. Biomaterial fabrication and cell encapsulation
Custom-made RGD-coupled alginate with high glucouronic acid content ((NovaMatrix
FMC Biopolymer, Norway) was utilized in this study. The RGD-coupled alginate was
purified and partially oxidized (5%) to increase its degradability according to published
methods [23, 24]. Subsequently, the alginate was mixed with anti-BMP2 mAb (25 "g/mL)
or control non-specific isotype mAb by vigorous stirring.
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hBMMSCs at a density of 2 × 106 cells per mL of alginate solution were encapsulated in
RGD-coupled alginate loaded with either mAb or non-specific Iso mAb. Formation of
microspheres was accomplished by extruding droplets of the alginate mixture through a
syringe into a solution of 100 mM calcium chloride. The microspheres were incubated at
37°C for 45 min and washed three times in DMEM without supplements.
2.5. In vitro release kinetics study
The kinetics of mAb release from alginate microspheres was evaluated by suspending the
mAb-loaded alginate microspheres in 50 mL of PBS (pH=7.4). At various time points (1, 3,
7, and 14 days), the amount of released mAb was determined by UV absorption
spectroscopy (Beckman, Brea CA). Retained mAb was detected with FITC-conjugated goat
anti-mouse IgG antibody (Santa Cruz Biotechnology Inc, CA) and measured using confocal
laser scanning microscopy (CLSM).
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2.6. Human BMMSC-mediated antibody assisted bone regeneration in vivo
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The USC Institutional Animal Care and Use Committee approved all procedures involving
vertebrate animals. Human BMMSCs were encapsulated in anti-BMP2 mAb-loaded alginate
hydrogel microspheres and transplanted into a 5 mm diameter critical size calvarial defect in
5-month-old Beige nude XID III (NU/NU) mice (Harlan Laboratories, Livermore, CA).
Immunocompromised mice were selected to avoid immunogenic and graft-rejection
responses due to the human origin of the stem cells.
A total of 20 NU/NU mice were used as hosts and had calvarial defects treated in one of the
following ways: encapsulated hBMMSCs (n=4); encapsulated hBMMSCs + anti-BMP2
mAb (25 "g/mL) (n=4); alginate microspheres + anti-BMP2 mAb (n=4); alginate
microspheres + rhBMP2 (25 "g/mL) (n=4); alginate microspheres + non-specific isotype
mAb (n=4). Animals were sacrificed 8 weeks after transplantation.
2.7. Micro-CT Analysis
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Upon sacrifice at 8 weeks following transplantation, the calvarial defects were examined
using a high-resolution micro CT system (MicroCAT II, Siemens Medical Solutions
Molecular Imaging, Knoxville, TN) to evaluate the healing of the defects. The specimens
were scanned every 10 "m at 60 kV and 110 "A at a spatial resolution of 18.7 "m (Voxel
dimension) and three-dimensional (3D) histomorphometric analysis was performed on the
resulting images. Bone volume fraction divided by total volume (BV/TV) of newly
regenerated bone for each stem cell-alginate construct was calculated using Amira software
(Visage Imaging Inc. San Diego CA).
2.8. Histology, immunohistochemical and immunofluorescent staining
For histological examination, specimens were fixed in 10% formalin solution and
decalcified with 10% EDTA for four weeks. Samples were dehydrated in an ascending
series of ethanol and embedded in paraffin. Sections of 6 "m thickness were prepared using
a microtome and mounted on subbed glass slides. Four randomly selected cross sections
from each implant were stained with hematoxylin and eosin (H&E) or Masson’s Trichrome
stains.
To identify the origin of the cells, paraffin-embedded sections were incubated with a
primary antibody directed against human mitochondria (Chemicon, Billerica, MA) at 1:200
dilution and the immune complex was detected using an immunoperoxidase ABC kit (HRP,
Vector Laboratories, Burlingame, CA). Sections were counterstained with hematoxylin.
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For immunohistochemical analysis, de-paraffinized sections were washed, and non-specific
endogenous peroxidase activity was quenched by immersing in 3% H2O2/methanol for 15
min. Sections were incubated with primary antibody (1:200–1:300 dilution) for 1 h.
Immunohistochemistry examination was performed on sections using anti-Runx2 (Santa
Cruz Biotechnology, 1:100 dilution) and anti-BMP2 (Abcam, 1:200 dilution) and
counterstaining with hematoxylin.
2.9. Statistical analysis of data
Quantitative data were expressed as mean ± standard deviation (SD). One-way and two-way
analyses of variance (ANOVA) followed by Tukey’s test at a significance level of ! = 0.05
were used for the comparison among multiple sample means.
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3. Results
3.1 Binding of BMP-2/Anti-BMP2 immune complex to hBMMSCs
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In order to assess the ability of the immune complex formed between the murine anti-BMP2
mAb and rhBMP2 ligand to bind with the hBMMSC BMP-2 cellular receptor, an in vitro
flow cytometric analysis was utilized. Flow cytometric analysis confirmed significant
binding of hBMMSC receptors with the anti-BMP-2 mAb and BMP2 ligand immune
complex (Fig. 1a). Negative controls consisting of non-specific isotype-matched mAb (Iso
mAb) or hBMMSCs alone showed no binding.
3.2. Osteogenic differentiation of hBMMSCs in vitro in the presence of anti-BMP2 mAb
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An in vitro model was developed to evaluate the effect of the anti-BMP2 mAb + rhBMP2
immune complex on the differentiation of stem cells. hBMMSCs were cultured in four
different conditions: 1) rhBMP2 (positive control); 2) anti-BMP2 mAb + rhBMP2 immune
complex; 3) Non-specific Iso mAb (negative control); and 4) media alone without
supplementation (negative control). The osteogenic differentiation of hBMMSCs was
analyzed using Alizarin red S staining. After 2 weeks, hBMMSCs from the positive control
and experimental groups both differentiated into positive Alizarin red S staining nodules,
indicative of their osteogenic fate (Fig. 1b), while neither of the two negative control groups
exhibited positive Alizarin red S dye staining. As expected, no statistically significant
difference (p>0.05) was found between cells cultured in the presence of rhBMP2 ligand
alone and those cultured with the immune complex formed by anti-BMP2 mAb + rhBMP2
ligand, supporting the interpretation that the immune complex of anti-BMP2 mAb +
rhBMP2 ligand actively binds to BMP receptors located on the hBMMSCs and contributes
to their osteogenic differentiation (Fig. 1b). The results from our Western blot analysis
correlated well with the data from the histochemical staining. Increased expression levels for
the osteoblastic-specific molecule, Runx2, were detected in specimens cultured for two
weeks in the presence of anti-BMP2 mAb + rhBMP2 ligand immune complex (Fig. 1c).
Similarly, cells cultured in the presence of anti-BMP2 mAb + rhBMP2 ligand immune
complex revealed up-regulation of phospho-Smad1. In contrast, cells maintained in the
presence of non-specific isotype mAb failed to activate the BMP signaling pathway, as
shown by their very modest levels of phoso-Smad1 and Runx2 expression.
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The ALP activity levels observed for hBMMSCs maintained in different culture conditions
are presented in Figure 1d. High levels of ALP activity were observed for hBMMSCs, both
in the presence of rhBMP2 ligand alone and in the presence of anti-BMP2 mAb + rhBMP2
ligand immune complex, manifesting peak activity during the second week of culture.
However, no statistically significant difference was observed in the amount of ALP activity
between cells treated with the BMP2 ligand alone or the anti-BMP2 mAb + rhBMP2
immune complex at any time interval examined (p>0.05). In contrast, only modest ALP
activity was observed for the cells grown in either medium alone or with non-specific
isotype mAb (p<0.01).
3.3. Development and characterization of stem cell-based delivery system to improve bone
tissue regeneration
Here, we describe the design of a system for encapsulating MSCs in RGD-alginate
microspheres with an average diameter of 1mm (Fig 2a). Microscopic images of stem cellloaded microspheres revealed a uniform cell distribution (Fig. 2b). The design was enhanced
by the incorporation of anti-BMP2 mAb (25 "g/mL) via absorption during the creation of
the microspheres. The release profile of mAb from the alginate microspheres showed
sustained release for up to 14 days (Fig. 2c). Moreover, the microspheres still retained anti-
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BMP2 mAb after 14 days, as revealed by immunofluorescent staining with an FITCconjugated goat anti-mouse IgG antibody (Fig. 2d).
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3.4. Human BMMSCs and mAb contributed to bone regeneration in a critical size calvarial
defect model
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We hypothesized that stem cell-mediated bone regeneration could be enhanced with the
addition of therapeutic antibodies to attract and tether host-derived BMP ligands, and that
such an integrated system would constitute a promising platform for bone tissue engineering
due to its ability to modulate the BMP signaling pathway. In order to test this platform, we
applied mAb-loaded RGD-alginate microspheres with 2 × 106 encapsulated hBMMSCs into
5 mm critical-sized cavarial defects in immune-compromised mice. Samples consisting of
encapsulated hBMMSCs alone in alginate or rhBMP2 alone in alginate were used as the
positive controls, while alginate loaded with non-specific isotype mAb was used as the
negative control. The quantity and quality of bone regenerated in the calvarial defect sites
were evaluated after 8 weeks using micro-CT and histological analyses. Micro-CT analysis
(Fig. 3a) demonstrated the greatest amounts of bone repair in the experimental group, which
received alginate hydrogel containing anti-BMP2 mAb and encapsulated hBMMSCs.
Quantitative analysis of the micro-CTs showed that the positive control groups (e.g.
encapsulated hBMMSCs and encapsulated anti-BMP2 mAb) formed less bone than the
experimental group that combined the anti-BMP2 mAb with encapsulated hBMMSCs
(p<0.05) (Fig. 3b). The negative control group regenerated the smallest amount of bone of
all the groups during the experimental period (p<0.05).
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Histological evidence supported the micro-CT observations demonstrating that the
hBMMSC-mediated, mAb-assisted concept significantly increased the amount of bone
tissue formed within the critical-sized calvarial defects (Fig. 3c). The tissue architecture
revealed that the bone had a lamellar pattern, contained viable osteocytes, and was rimmed
with osteoblasts engaged in bone formation. There was no evidence of dystrophic
calcifications. Osteocytes and osteoblasts were evident in the regenerated bone from
samples treated with anti-BMP2 mAb alone, hBMMSCs alone, and rhBMP2 alone. On the
other hand, histological analysis revealed that sites implanted with alginate loaded with nonspecific isotype mAb (negative control) contained only fibrous and vascular connective
tissue components consisting of interwoven bundles of collagenous fibers and unresorbed
alginate hydrogel (Fig. 3c). Histomorphometric analysis indicated that hBMMSCs
encapsulated in alginate with anti-BMP2 mAb formed significantly greater (p<0.05)
amounts of mineralized tissue than either alginate-encapsulated hBMMSCs or non-specific
isotype mAb, and indeed that the hBMMSC + anti-BMP2 mAb combination was able to
repair the critical-sized defects (Fig. 3d). Quantitative analysis demonstrated significant
improvement in the amount of bone regenerated by hBMMSCs and anti-BMP2 mAb
together (p < 0.05).
To further characterize MSC-mediated, antibody-assisted bone formation, we utilized
immunohistochemical staining. The samples consisting of anti-BMP2 mAb absorbed to
alginate encapsulating hBMMSC, anti BMP2-mAb alone, and alginate encapsulated
hBMMSC revealed the shared capacity to attract and hold BMP2 ligands, as revealed by
positive immunostaining (Fig 4a, upper panel). Not surprisingly, the samples treated with rhBMP2 also revealed the presence of the BMP ligand, while the non-specific isotype mAb
failed to trap the BMP2 ligand. We also performed semi-quantitative analysis for the
presence of BMP2 ligand (see upper panel, Fig. 4a), which confirmed the attraction of
endogenous BMPs by the mAb (Fig. 4b). Similarly, the positive controls and experimental
samples revealed cells that express the bone transcription factor, Runx2, while the negative
control (non-specific isotype mAb) did not. Finally, the human origin of the osteoblasts and
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osteocytes was confirmed by their positive immunostaining with anti-human mitochondrion
antibody when hBMMSCs were engrafted (Fig. 4a lower panel).
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4. DISCUSSION
Current treatment modalities for bone regeneration in craniofacial reconstructive surgeries
and regenerative medicine more broadly consist of implantation with autogenous,
allogeneic, xenogenic, and synthetic biomaterials. There are many disadvantages associated
with autologous grafts, including a limited donor supply and the high rate of harvest
morbidity. The advent of allografts, xenografts, and synthetic biomaterials has enabled
clinicians to avoid some of the pitfalls associated with autografts; however, their efficacy is
restricted due to their lack of osteoinduction, unpredictable graft resorption, and unfavorable
mechanical properties [4-6]. A way of avoiding all of these materials and their drawbacks is
suggested by the fact that BMPs have been identified as the major mediators in bone
regeneration and formation. It is well known that exogenous administration of rhBMP2 can
initiate a healing cascade that mediates bone regeneration through the TGF-#/BMP signaling
pathway [25,26].
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Recombinant human bone morphogenetic protein 2 (rhBMP2) has been widely used for
bone regenerative procedures, providing a promising alternative therapeutic option to
autologous bone grafting. However, there are several disadvantages attributed to the
application of rhBMP2. First, in order to be clinically effective, superphysiologic doses of
the growth factor are needed. In addition, the inability to sustain growth factor concentration
over extended periods of time leads to lower biological activity of recombinant BMP2.
Compounding these issues, rhBMP2 is a very expensive therapeutic modality [27-29].
Therefore, alternatives to rhBMP2 are desirable. Recently, Freire et al. reported a bone
regenerative therapy, in which anti-BMP2 monoclonal antibodies were capable of capturing
endogenous BMP growth factors from the local host-graft site, with demonstrated efficacy
in promoting bone repair and regeneration [20, 21]. Additionally, other studies have shown
that a short treatment of MSCs with BMP2 ligand stimulated Runx-2 and osteopontin gene
expression, leading to enhanced bone regeneration [30, 31]. Therefore, in this study, we
developed an MSC delivery system that can be preloaded with anti-BMP2 mAb. We
hypothesized that mesenchymal stem cells combined with antibodies against BMP2 could
provide a promising platform for bone tissue engineering through capturing endogenous
BMPs.
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Using mesenchymal stem cells to regenerate bone comes with its own distinct set of
advantages. The application of cell-delivery substrates, which provide a suitable
microenvironment for tissue regeneration, is considered to be crucial for the complete repair
of bony defects [32-34]. Biomaterial design has focused on controlling the material
chemistry to direct cell and tissue responses and to promote highly specific binding
interactions between the material and surrounding cells [35-37]. It has been reported that
scaffolds seeded with appropriate MSCs can provide a suitable microenvironment with
nutrients for prolonged cell viability and osteogenic potential, making this approach a
promising treatment modality [38,39]. In our study, we sought to design an appropriate
microenvironment by engineering the physiochemical properties of the extracellular MSC
microenvironment in order to tailor the niche characteristics and direct cell differentiation
and phenotype. To accomplish this, we developed an alginate hydrogel scaffold loaded with
anti-BMP2 mAbs. Alginates are of particular interest for bone engineering applications due
to their unique properties, including injectability and biodegradability [40,41]. Alginate can
provide a 3D scaffold that facilitates the spatial distribution of MSCs, thus resulting in a
structural organization that resembles the native in vivo microenvironment.

Biomaterials. Author manuscript; available in PMC 2014 September 01.

Moshaverinia et al.

Page 9

NIH-PA Author Manuscript

An injectable alginate-hydrogel microsphere loaded with anti-BMP2 mAb was developed
and described here as a stem cell delivery system for potential application in bone tissue
engineering. We showed the feasibility of applying hBMMSCs encapsulated in alginate
hydrogel microspheres preloaded with anti-BMP2 mAb as a treatment modality for bone
regeneration. This approach utilizes the regenerative potential of anti-BMP2 mAb to capture
endogenous BMP2 and present it to MSCs. We confirmed through multiple independent
methods that stem cell-mediated osteogenesis was indeed assisted by the mAb capturing
endogenous BMP2. Micro-CT and histological analyses confirmed a significant increase in
the amount of bone repair in the presence of a combination of hBMMSCs and anti-BMP2
mAb.
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Our in vitro assay confirmed the presence of cross-reactivity between hBMMSC BMP
receptors with the anti-BMP2mAb + rhBMP2 immune complex, while the non-specific
isotype control mAb (Iso mAb) immune complex with rhBMP2 failed to bind to BMP
receptors on the MSCs (due to unfavorable binding mode). We further investigated the
molecular mechanism governing osteogenic differentiation of hBMMSCs in the presence of
mAb in an in vitro model by developing a culture system to study this molecular
mechanism. The data confirmed that bone regeneration is modulated by the BMP signaling
pathway through the anti-BMP2 mAb capturing BMP2 ligands. In the presence of antiBMP2 mAb, increased expression of the positive modulators of osteogenesis, p-Smad 1 and
Runx2, was observed. These findings were well supported by biomineralization results
reported by Alizarin red S staining showing that anti-BMP2 mAb + rhBMP2 immune
complex successfully induced osteogenic differentiation of hBMMSCs, while hBMMSCs in
the presence of non-specific isotype control mAb failed to do so.
We further demonstrated the possibility of enhancing the osteo-differentiation of hBMMSC
encapsulated in alginate microspheres in the presence of anti-BMP2 mAb in vivo. When the
encapsulated hBMMSCs were transplanted into critical-size calvarial defects in mice, they
regenerated bone tissue to repair critical-sized defects that by definition would never repair
without intervention. In addition, the osteoblasts and osteocytes within the newly-formed
bone tissue expressed the osteogenic markers Runx2 and BMP2, as shown by
immunodetection. As expected, in the presence of anti-BMP2 mAb, we observed a
significant increase in the area that tested positive for BMP2 ligands. Furthermore, we
confirmed the human origin of the cellular components of the bone tissue produced by the
engrafting hBMMSCs using specific antibodies against human mitochondria.
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Based on our accumulated data, the efficacy of hBMMSC-mediated mAb-assisted bone
regeneration can attributed to the ability of anti-BMP2 monoclonal antibody to capture
endogenous BMP2 ligands and hence to direct differentiation of hBMMSCs toward
osteogenic lineage through modulating the BMP signaling pathway.
Conclusions
This study describes a technique for leveraging a system of mesenchymal stem cellmediated, mAb-assisted bone regeneration. Here we describe a bone regeneration strategy
based on in vitro and in vivo experiments which demonstrate the capacity of hBMMSCs to
respond to the inductive signals provided by an anti-BMP2 mAb. We utilized the ability of
anti-BMP2 mAb to trap and tether endogenous BMP2 ligands for the directed osteodifferentiation of hBMMSCs using an RGD-alginate microencapsulation system. The
advantages of this system include its simplicity and ease with which it can be modified to
encapsulate hBMMSCs in an injectable and biodegradable alginate hydrogel, yielding a 3dimensional, cell delivery scaffold for bone tissue engineering.
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Figure 1. Anti-BMP2 mAb + rhBMP-2 immune complex binds to BMP receptors on hBMMSCs
and contributes to osteogenic differentiation of hBMMSCs in vitro
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(a) Analysis by flow cytometry of murine anti-BMP2 monoclonal antibody (mAb) immune
complex bound to human recombinant BMP2 ligand (rhBMP2) interacting with the BMP
receptors on hBMMSCs. The median fluorescent intensity (MFI) revealed binding between
the immune complex with the BMP receptors located on the hBMMSCs. hBMMSCs alone
and non-specific isotype mAb (Iso mAb) failed to reveal BMP2 ligand binding. (b)
Qualitative and quantitative measurement for calcium ion localized to biomineralized nodule
using Alizarin red S dye formed by hBMMSCs after treatment with either BMP2 ligand or
anti-BMP2 mAb + rhBMP2 and cultured for two weeks. (c) Western blot analysis showing
changes in the levels of expression of critical regulators of osteogenesis by hBMMSCs. The
levels of phospho-Smad1 (p-Smad 1) and Runx2 transcription factor are elevated in
hBMMSCs grown in the presence of anti-BMP2 monoclonal antibody + rhBMP2 or
rhBMP2 ligand alone compared to cells maintained in the presence of non-specific isotype
mAb (Iso mAb). (d) Alkaline phosphatase (ALP) activity for hBMMSCs in the presence or
absence of anti-BMP2 mAb. The ALP value was normalized to the DNA concentration,
with units of mM pNpp min-1/"g DNA. *P<0.05, **P<0.001, ***P<0.001, n=5 for each
group.
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Figure 2. Development of the hBMMSC microencapsulation system with sustained mAb release
characteristics in vitro

(a) Schematic presentation of the MSC-based co-delivery system containing anti-BMP2
mAb. (b) Bright field image of the alginate beads showing they retain their spherical shape
with a uniform cell distribution (average capsule diameter 1 ± 0.1 mm). (c) Characterization
of the in vitro release profile of anti-BMP2 mAb-loaded alginate microspheres showing
sustained release of anti-BMP2 mAb from alginate microspheres. mAb release is calculated
from the total amount of anti-BMP2 mAb released after 14 days. (d) Confocal laser scanning
microcopy analysis showing immobilized anti-BMP2 mAb (green signal) on microspheres
after staining with FITC-conjugated goat anti-mouse secondary antibody and detected by
confocal laser fluorescent microscopy showing that anti-BMP2 mAb is retained on the
microspheres for up to two weeks in vitro.
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Figure 3. hBMMSCs encapsulated in RGD-alginate microspheres loaded with anti-BMP2 mAb
contribute to bone regeneration in a critical-size calvarial defect model

(a) Micro-CT results of bone repair in mouse calvarial defects. Regenerated bone is pseudocolored red. (b) Semi-quantitative analysis of bone formation based on micro-CT images; (c)
Microanatomic representation of repair of critical-size defects in the mouse calvaria after 8
weeks of transplantation at high (× 40) and low (× 4) magnifications stained with H&E.
Arrows point to osteocytes in lacunae (Alg: unresorbed alginate, CT: connective tissue). (d)
Histomorphometric analysis of calvarial defects showing the relative amount of bone
formation in the critical size calvarial defect model. *P<0.05, **P<0.01, n=4 for each group.
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Figure 4. Characterization of the origin and fate of MSCs after transplantation

(a) Upper Panel: Cells and alginate positive for BMP2 epitopes are stained brown. Middle
Panel: Cells expressing the bone-associated transcription factor Runx2 are stained brown
(black arrows). Lower Panel: The human origin of the engrafted cells is confirmed by
immunostaining with an antibody specific for human mitochondria (open arrows). Tissue
formed in the negative control samples (e.g., non-specific isotype mAb [Iso mAb] failed to
express either BMP2 or Runx2 and did not contain cells of human origin. (b) Semiquantitative analysis of the percentage of cells and alginate positive for BMP2 protein taken
from images shown in the upper panel of (a). *P <0.05, **P <0.01.
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